Bulletin de l'Academie Nationale de Medecine 2011-01-01

[Medical aspects of the medical treatment in dystonia].

David Grabli, Marie Vidailhet

Index: Bull. Acad. Natl. Med. 195(4-5) , 935-50, (2011)

Full Text: HTML

Abstract

Dystonias encompass a wide range of movement disorders characterized mainly by abnormal postures or movements. Because of this semiological and etiological heterogeneity, robust clinical trials are rare. Specific etiological treatments are available for only a few forms (e.g. Wilson's disease and dopa-responsive dystonia), which places the emphasis on symptomatic treatment. This is based on the combinations of three complementary approaches: drug therapy (anticholinergics, tetrabenazine and benzodiazepines are first-line drugs, but many others have been tested in small clinical trials), botulinium toxin injections in case of focal dystonia or focal targets in patients with more widespread dystonia, and physiotherapy. This review provides a short overview of available treatments and proposes a basic therapeutic strategy for dystonic patients.

Related Compounds

  • Tetrabenazine

Related Articles:

The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion.

2015-04-01

[Psychopharmacol. Ser. 232(7) , 1313-23, (2015)]

Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.

2015-08-01

[Acta Neuropsychiatr. 27 , 228-34, (2015)]

"Mixed" anionic and non-ionic micellar liquid chromatography for high-speed radiometabolite analysis of positron emission tomography radioligands.

2013-03-15

[J. Chromatogr. A. 1281 , 54-9, (2013)]

Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.

2013-12-04

[J. Neurosci. 33(49) , 19120-30, (2013)]

GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.

2013-10-01

[J. Neurochem. 127(2) , 177-86, (2013)]

More Articles...